Kala Pharmaceuticals Stock Current Ratio
| KALA Stock | USD 6.55 0.12 1.87% |
Kala Pharmaceuticals fundamentals help investors to digest information that contributes to Kala Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Kala Stock. The fundamental analysis module provides a way to measure Kala Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kala Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 6.33 | 6.47 |
Kala | Current Ratio |
Kala Pharmaceuticals Company Current Ratio Analysis
Kala Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Kala Pharmaceuticals Current Ratio | 2.54 X |
Most of Kala Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kala Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Kala Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Kala Pharmaceuticals is extremely important. It helps to project a fair market value of Kala Stock properly, considering its historical fundamentals such as Current Ratio. Since Kala Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kala Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kala Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Kala Current Ratio Historical Pattern
Today, most investors in Kala Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kala Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Kala Pharmaceuticals current ratio as a starting point in their analysis.
Kala Pharmaceuticals Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Kala Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Kala Pharmaceuticals has a Current Ratio of 2.54 times. This is 12.71% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current ratio for all United States stocks is 17.59% lower than that of the firm.
Kala Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kala Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kala Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kala Pharmaceuticals by comparing valuation metrics of similar companies.Kala Pharmaceuticals is currently under evaluation in current ratio category among its peers.
Kala Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kala Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kala Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Kala Fundamentals
| Return On Equity | -2.48 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 17.48 M | ||||
| Shares Outstanding | 4.61 M | ||||
| Shares Owned By Insiders | 5.14 % | ||||
| Shares Owned By Institutions | 48.13 % | ||||
| Number Of Shares Shorted | 37.47 K | ||||
| Price To Earning | (0.52) X | ||||
| Price To Book | 4.32 X | ||||
| Price To Sales | 1.16 X | ||||
| Gross Profit | 1.33 M | ||||
| EBITDA | (36.08 M) | ||||
| Net Income | (42.2 M) | ||||
| Cash And Equivalents | 44.57 M | ||||
| Cash Per Share | 30.44 X | ||||
| Total Debt | 36.32 M | ||||
| Debt To Equity | 4.77 % | ||||
| Current Ratio | 2.54 X | ||||
| Book Value Per Share | 2.72 X | ||||
| Cash Flow From Operations | (27.93 M) | ||||
| Short Ratio | 1.91 X | ||||
| Earnings Per Share | (11.67) X | ||||
| Target Price | 15.0 | ||||
| Number Of Employees | 43 | ||||
| Beta | -2.14 | ||||
| Market Capitalization | 29.64 M | ||||
| Total Asset | 55.95 M | ||||
| Retained Earnings | (629.41 M) | ||||
| Working Capital | 44.52 M | ||||
| Current Asset | 84.65 M | ||||
| Current Liabilities | 10.53 M | ||||
| Net Asset | 55.95 M |
About Kala Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kala Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kala Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kala Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kala Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kala Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kala Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kala Pharmaceuticals Stock:Check out Kala Pharmaceuticals Piotroski F Score and Kala Pharmaceuticals Altman Z Score analysis. For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.67) | Quarterly Revenue Growth (1.00) | Return On Assets (0.40) | Return On Equity (2.48) |
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.